On 17 June 2020, WHO announced that the hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment was being stopped.
The trial's Executive Group and principal investigators made the decision based on evidence from the Solidarity trial, UK's Recovery trial and a Cochrane review of other evidence on hydroxychloroquine.
Data from Solidarity (including the French Discovery trial data) and the recently announced results from the UK's Recovery trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care.
6298
已经加入羟氯喹试验组的人将会怎样？
What will happen to the people who were already enrolled in the hydroxychloroquinearm of the trial?
6299
团结试验的研究人员将不再随机让更多患者服用羟氯喹。
Investigators will not randomize further patients to hydroxychloroquine in the Solidarity trial.
6300
对于在试验中已经开始服用羟氯喹但尚未完成疗程的患者，可由指导医生斟酌决定或完成疗程或停止治疗。
Patients who have already started hydroxychloroquine but who have not yet finished their course in the trial may complete their course or stop at the discretion of the supervising physician.